| 1  | TITLE   |
|----|---|
| 2  | The cost of diagnostic uncertainty: A prospective economic analysis of febrile children |
| 3  | attending an NHS Emergency Department   |
| 4  |   |
| 5  | AUTHORS   |
| 6  | Simon Leigh MSc, Alison Grant RCN, Nicola Murray MBChB, Brian Faragher PhD,             |
| 7  | Henal Desai MBChB, Samantha Dolan MBChB, Naeema MO Cabdi MBChB, James B                 |
| 8  | Murray MBChB, Yasmin Rejaei MBChB, Stephanie Stewart MBChB, Karl Edwardson,             |
| 9  | Jason Dean MMS, Bimal Mehta MBChB, Shunmay Yeung MBChB, PhD, Frans Coenen               |
| 10 | PhD, Louis Niessen MD, PhD#, and Enitan D Carrol MBChB, MD, FRCPCH#                     |
| 11 | #Contributed equally  |
| 12 |   |
| 13 | <u>AFFILIATIONS</u>   |
| 14 |   |
| 15 | Alison Grant, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, L12     |
| 16 | 2AP, UK Alison.grant@alderhey.nhs.uk  |
| 17 |   |
| 18 | Nicola Murray, The Royal Liverpool University Hospital, Prescot St, Liverpool, L7 8XP,  |
| 19 | UK Nicolarosemurray@doctors.org.uk  |
| 20 |   |
| 21 | Brian Faragher, Medical Statistics Unit, Department of Clinical Sciences, Liverpool     |
| 22 | School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.                     |
| 23 | Brian.faragher@lstmed.ac.uk   |
| 24 |   |

| 25 | Henal Desai, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK               |
|----|--|
| 26 | HenalDesai@hotmail.com   |
| 27 |  |
| 28 | Samantha Dolan, Royal Bolton Hospital, Minerva Road, Farnworth, BL4 0JR, UK          |
| 29 | Samatha.dolan@boltonft.nhs.uk  |
| 30 |  |
| 31 | Naeema MO Cabdi, School of Medicine, University of Liverpool, Cedar House,           |
| 32 | Liverpool, L69 3GE, UK nmo.cabdi@gmail.com   |
| 33 |  |
| 34 | James B Murray, Queen Elizabeth Hospital, Birmingham, Mindelsohn Way, B15 2TH,       |
| 35 | UK James.murray2@uhb.nhs.uk  |
| 36 |  |
| 37 | Yasmin Rejaei, Pinderfields District General Hospital, Aberford Road, Wakefield, WF1 |
| 38 | 4DG, UK  |
| 39 | yasmin.rejaei@midyorks.nhs.uk  |
| 40 |  |
| 41 | Stephanie Stewart, Wirral University Teaching Hospital, Arrowe Park Road, Wirral,    |
| 42 | CH49 5PE, UK Stephanie.Stewart@nhs.net   |
| 43 |  |
| 44 | Karl Edwardson, Information Department, Alder Hey Children's NHS Foundation Trust,   |
| 45 | Eaton Road, Liverpool, L12 2AP, UK Karl.Edwardson@alderhey.nhs.uk                    |
| 46 |  |
| 47 | Jason Dean, Finance Department. Alder Hey NHS Foundation Trust, Eaton Road,          |
| 48 | Liverpool L12 2AP, UK Jason.Dean@alderhey.nhs.uk                                     |
| 49 |  |
| 50 | Bimal Mehta, Emergency Department, Alder Hey Children's NHS Foundation Trust,        |
| 51 | Eaton Road, Liverpool L12 2AP, UK bimal.mehta@nhs.net                                |

| 52 |   |
|----|---|
| 53 | Shunmay Yeung, Department of Clinical Research, MARCH Centre for Maternal,              |
| 54 | Adolescent, Reproductive and Child Health, London School of Hygiene and Tropical        |
| 55 | Medicine, Keppel Street, London WC1E 7HT, UK Shunmay.yeung@lshtm.ac.uk.                 |
| 56 | Frans Coenen, Department of Computer Science, The University of Liverpool, Ashton       |
| 57 | Building, Ashton Street, Liverpool, L693BX, UK Coenen@liverpool.ac.uk                   |
| 58 |   |
| 59 | # Louis Niessen, Department of International Public Health and Clinical Sciences,       |
| 60 | Liverpool School of Tropical Medicine and University of Liverpool, Liverpool, United    |
| 61 | Kingdom, UK, and Johns Hopkins School of Public Health, USA,                            |
| 62 | Louis.Niessen@lstmed.ac.uk.   |
| 63 |   |
| 64 | # Enitan D Carrol, Institute of Infection and Global Health, University of Liverpool, 8 |
| 65 | West Derby St, Liverpool, L7 3EA, UK edcarrol@liv.ac.uk                                 |
| 66 |   |
| 67 | # Contributed equally   |
| 68 |   |
| 69 | CORRESPONDING AUTHOR  |
| 70 |   |
| 71 | Simon Leigh, Institute of Infection and Global Health, University of Liverpool, 8 West  |
| 72 | Derby St, Liverpool L69 7BE. Simon.leigh@liverpool.ac.uk. +44 7503 955 592              |
| 73 |   |
| 74 |   |
| 75 |   |
| 76 |   |
| 77 |   |

### **ABSTRACT**

### **Background**

Paediatric fever is a common cause of emergency department (ED) attendance. A lack of prompt and definitive diagnostics makes it difficult to distinguish viral from potentially life-threatening bacterial causes, necessitating a cautious approach. This may result in extended periods of observation, additional radiography, and the precautionary use of antibiotics (ABs) to deal with bacterial foci. This study examines resource use, service costs, and health outcomes.

#### Methods

We studied an all-year prospective, comprehensive, and representative cohort of 6,518 febrile children (aged <16 years), attending Alder Hey Children's Hospital, an NHS-affiliated paediatric care provider in the North West of England, over a one-year period. Performing a time-driven and activity-based micro-costing, we estimated the economic impact of managing paediatric febrile illness, with focus on nurse/clinician time, investigations, radiography and inpatient stay. Using bootstrapped generalized linear modelling (GLM, gamma, log), we identified the patient and healthcare provider characteristics associated with increased resource use, applying retrospective case-note identification to determine rates of potentially avoidable AB prescribing.

### Results

Infants aged less than three months incurred significantly higher resource use than any other age-group, at £1000.28 [95%CI £82.39-£2,993.37] per child, (p<0.001); while lesser experienced doctors exhibited 3.2-fold [95%CI 2.0-5.1-fold] higher resource use than consultants, (p<0.001). Approximately 32.4% of febrile children received antibiotics and 7.1% were diagnosed with bacterial infections. Children with viral illnesses for whom antibiotic prescription was potentially avoidable incurred 9.9-fold [95%CI 6.5-13.2-fold] cost increases compared to those not receiving antibiotics, equal to an additional £1,352.10 per child; predominantly resulting from a 53.9 hour increase in observation and inpatient stay (57.1 vs. 3.2 hours). Bootstrapped GLM suggested that infants aged below three months, those prompting a respiratory rate "red flag", treatment by lesser-experienced doctors and Manchester Triage System (MTS) yellow or higher were statistically significant predictors of higher resource use in 100% of bootstrap simulations.

### Conclusion

The economic impact of diagnostic uncertainty when managing paediatric febrile illness is significant, and the precautionary use of antibiotics is strongly associated with increased costs. The use of ED resources is highest among infants (aged less-than-three months), and those infants managed by lesser experienced doctors, independent of clinical severity. Diagnostic advances which could increase confidence to withhold antibiotics, may yield considerable efficiency gains in these groups; where the perceived risks of failing to identify potentially life-threatening bacterial infections are greatest.

### **Keywords**

Febrile, fever, pyrexia, children, health economics, cost of illness, antibiotics, United

128 Kingdom

# **BACKGROUND**

Fever is a common cause of presentation to paediatric emergency departments (EDs),<sup>1</sup> accounting for ~20% of all visits;<sup>2</sup> but despite its frequent occurrence, the aetiology of fever is diverse.<sup>3</sup> Most children with fever will suffer from self-limiting viral illnesses, however viral, bacterial, and severe bacterial infections (SBIs) may result in almost identical clinical presentations in infants; making diagnosis based on presentation, history, and clinical judgement alone a difficult task.

While a clear focus of bacterial infection may be present with presentations of acute otitis media (AOM) or urinary tract infection (UTI), occult bacteremia can also occur in children who appear otherwise well, and fever without focus is a common presentation, particularly so in those aged <36 months.<sup>4,5,6</sup> However, occurring in as few as 1% of febrile children<sup>4,5</sup>, these 'hidden' bacterial infections represent a needle in the haystack; and the challenge for clinicians is to accurately identify children at risk of bacterial

infections. While it is possible that they may resolve spontaneously, for those in whom they do not, life-threatening and potentially life-changing complications can develop, 4,7,8 with adverse outcomes in each survivor of severe meningococcal disease resulting in lifelong treatment costs of ~£1.3m.9

As a result, a cautious stepped approach to the management of the febrile child is common, characterised by extended periods of observation, investigations, radiography, and the precautionary use of antibiotics, often prior to definitive evidence of bacterial foci. Unfortunately, such interventions are invasive, can be painful, and are likely to prolong a child's visit to the ED; contributing to extended ED waiting times, and driving the use of scarce ED healthcare resources.

The test currently providing the greatest degree of certainty in diagnosing invasive bacterial infections, the blood culture; typically takes 12-48 hours to provide results; has a sensitivity of just 30-40%<sup>11</sup>, and a significant false positive rate due to contamination with commensal bacteria from the skin and mucosal surfaces. <sup>12</sup> This limits the diagnostic utility of the blood culture to clinicians required to make decisions concerning the management of the febrile child in real-time; which in turn increases the importance of sufficient observation time, repeated-blood/urine investigations and clinical judgement. With the potential over-treatment of febrile children on the one-hand, and the prospect of failing to identify potentially life-threatening SBIs on the other; a lack of timely and reliable indicators of febrile aetiology, coupled with a natural tendency for risk aversion when treating children, has resulted in a substantial financial burden to healthcare systems worldwide. However, to date, just a handful of studies, predominantly US-based and conducted between six and 25 years ago in young children; have examined the economic impact of paediatric febrile illness. <sup>13-16</sup>

Using a bottom-up time-driven and activity-based costing model (TDABC), the aims of this research were to (1) estimate the economic impact of managing febrile illness episodes in children of all ages and presenting complaints, in an NHS paediatric ED setting, (2) to identify how management practices and costs vary with factors including patient age, and the experience of treating clinicians, and, (3) to provide insights regarding where any diagnostic advances currently under development, including molecular diagnostics, protein biomarkers, and point-of-care (POC) testing technologies, are likely to yield the greatest clinical and socioeconomic value, by reducing clinical uncertainty increasing confidence to withhold antibiotics.

## **METHODS**

#### Participants & Methods

This study applies time-driven activity-based costing (TDABC), a bottom-up approach to healthcare costing, which maps pathways observed during routine clinical practice, identifies all points and durations of interaction therein, and assigns time-dependent costs to each constituent. The costs of non-time-dependent activities, including tariff-based ancillary investigations, are subsequently added to provide a representative activity-weighted cost per completed treatment episode.

A total of 8,552 consecutive febrile children, with a temperature above 38°C at presentation, or below 38°C with an unverified parent-reported history of fever up to 3 days previous, were prospectively identified. All children visited Alder Hey Children's NHS Foundation Trust, a large paediatric specialist care provider in the North West of England, between 1st September 2012 and 31st August 2013. Children were excluded if (1) data concerning key components of their stay, including the treatments provided, or healthcare personnel seen, were missing or incomplete, or

(2) if there were pre-existing medical conditions likely to modify ED care pathways from those of the average 'otherwise well' patient, including paediatric oncology patients.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

206

205

A schematic of the clinical pathway used for this study is provided in Fig 1. Children were initially seen by a qualified ED nurse who conducted an initial evaluation, using the Manchester Triage System (MTS).<sup>17</sup> MTS assessments follow a flow chart based on the patient's reason for contacting the ED. The chart begins by identifying possible criteria indicating life-threatening conditions for the patient, and if none of these conditions are present, the nurse continues along the flow chart asking questions until the nurse assigns the patient an appropriate category. The nurse's experience can contribute to the assessment, but on the other hand, the risk of the nurse missing serious conditions is reduced because the flow chart forces the nurse to ask key questions and make vital inquiries. Children were triaged as green 'standard', yellow 'urgent', orange 'very urgent' or red 'immediate attention'. For several children, borderline 'yellow/red' or 'orange/red' categories were applied. This was a result of uncertainty during triage, and such children had their MTS classification amended with increased or reduced urgency following a second opinion with a nurse or clinician. Diagnostic categories, defined as definite bacterial, probable bacterial or bacterial syndrome with low/no inflammatory markers, definite viral, probable viral, or viral syndrome with no/high inflammatory markers, trivial illness, inflammatory illness, and unknown/insufficient information, were applied retrospectively, based on an adapted algorithm from Herberg et al. 18 In any instance where uncertainty or disagreement occurred regarding the appropriate classification, these cases were marked and decided upon by two consultants specializing in paediatric infectious disease. All cases had notes, including CRP, neutrophils and sterile site pathogenic bacteria recorded such that diagnosis classifications could be quality checked, to ensure consistency. For this analysis, definite bacterial, probable bacterial and bacterial syndromes with low/no inflammatory markers, were collectively defined as 'bacterial

aetiologies', while definite viral, probable viral, and viral syndromes with no/high inflammatory markers were collectively defined as 'viral aetiologies'. Like other studies, <sup>19</sup> the prescription of antibiotics for patients with anything other than a bacterial aetiology of fever, were for this study, defined retrospectively as "potentially avoidable".

236

232

233

234

235

237

238

Fig. 1: Clinical pathway of paediatric febrile illness used for patient-level costing

239240

241242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Because time stamps documenting the duration of contact with healthcare personnel for various treatments and investigations are not routinely collected as part of NHS electronic patient records, these were imputed in one of two ways. Firstly, estimates were provided by staff actively involved in the provision of ED care. Secondly, prospective time-in-motion data were collected for a representative cohort of 71 febrile children presenting to Alder Hey Children's NHS Foundation Trust ED between January 6th and February 12th, 2017. Four 5th year medical students collected the data by 'shadowing' patients reporting to the book-in desk with fever as a symptom. Additionally, any patients suspected of fever by clinical teams (such as the nurse performing initial visual assessment) were additionally identified. The researchers followed patients through the ED, documenting all points of interaction with healthcare professionals using a stopwatch and a pre-designed case report form. Parental consent was obtained prior to data collection. Data were collected in four hourly blocks during the day (8a.m-4p.m), evening (4p.m-12a.m) and early morning (12a.m-4a.m), seven days a week. All children with a suspected fever were observed from the point of visual assessment, and their experience in the ED, timed using a stopwatch and documented in Microsoft® Excel. For any events which were not observed during implementation of the time-in-motion study, including clerical and administrative tasks such as writing up patient notes, these were estimated following a Delphi panel approach. In all such cases a number of estimates were obtained and the average time was used because tasks such as

Table 1: Staff time associated with components of the paediatric febrile illness pathway

265

| ACTIVITY  | MEAN DURATION (MINS) |
|---|----------------------|
| Triage time (Nurse)*  | 4.5                  |
| Clinician consultation time (MTS Green)*                                      | 16.2                 |
| Clinician consultation time (MTS Yellow)*                                     | 19.4                 |
| Clinician consultation time (MTS Orange)*                                     | 21.1                 |
| Clinician consultation time (MTS Red)*  | 22.7                 |
| Clinician time - Writing up patient notes#                                    | 10                   |
| Order blood/urine culture (Clinician)#  | 10                   |
| Arrange X-ray (Clinician)#  | 6                    |
| Book patient into the ED (Receptionist)#                                      | 2                    |
| Refer patient to other specialties (Clinician)#                               | 20                   |
| Insert cannula (Clinician)*   | 20                   |
| Provide antibiotics/other medicines (Nurse)#                                  | 5                    |
| Visual assessment triage (Nurse)*   | 2                    |
| Interpret results of ancillary investigations                                 |                      |
| (Clinician)#  | 10                   |
| *Collected during time-in-motion study  # Estimate provided by ED consultants |                      |

### Unit costs

Hourly salaries for healthcare personnel were provided by the patient-level costing department at the Trust. Except for clinicians, salaries for those working either (1) weekdays between 7pm and 7a.m, or, (2) at the weekend, had their hourly rate increased in line with NHS guidance on working unsocial hours.<sup>20</sup> Costs for non-time driven activities, including laboratory-based investigations, were obtained from the Trust's finance department and NHS reference costs 2015/16.21 Pharmaceuticals were assigned unit costs from the British National Formulary. As data concerning the precise antibiotics provided to patients were not available, we assumed that antibiotic prescribing was in line with the recommendations provided within NICE CG160.<sup>22</sup> Namely, where intravenous (IV) antibiotics were prescribed, both a third-generation cephalosporin (cefotaxime, ceftriaxone) and an anti-listeria agent were provided (amoxicillin, ampicillin) for infants under 1 month, and a third-generation cephalosporin alone if more than 1 month. In cases of empiric IV antibiotic therapy, it was assumed that a third-generation cephalosporin directed against Neisseria meningitidis, Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus and Haemophilus influenzae type b was provided. Where oral antibiotics were prescribed it was assumed that amoxicillin or cephalexin were provided as per local antimicrobial guidance.

Costs incurred during inpatient stay were obtained from NHS reference costs 2015/16. The tariff HRG PW20C (paediatric fever of unknown origin, CC score = 0) was utilised to reflect a 3-day short stay inpatient admission. As children could be admitted for anywhere between 1 and 72 hours under the reference tariff, this figure was divided through by 72 and multiplied by the number of hours of inpatient admission. Patients who exceeded the three-day limit, incurred an excess bed day charge which was applied from the fourth day until discharge.<sup>21</sup> Finally, indirect costs were estimated for each patient, using the 'full absorption approach'. This included the anticipated use of facilities such as toilets, and the time of administrative staff typing up and

sending discharge notes to patient's general practitioners. Societal costs, including parental absence from work, and children's absence from school were not included, as the analysis was conducted from a healthcare provider perspective. Due to the short time frame of the analysis, costs were not discounted. All unit costs were in 2017 prices and are provided within Table S1.

299

300

295

296

297

298

Table S1: Unit costs by component of paediatric febrile illness pathway

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

### Outcomes & statistical analysis

We present summary statistics to describe the characteristics of participants. Categorical variables were summarised by frequency and percentage, while continuous variables were reported as mean, standard deviation (SD), median, interquartile range (IQR), minimum and maximum values. Our primary outcome was the 'cost per completed febrile illness episode', with an 'episode' defined as the period from booking in to the ED to final discharge, enabling the possibility for re-attendances to be included. We additionally performed sub-group analyses to account for patient and healthcare provider heterogeneity. As our primary outcome data were both non-normally distributed, and characterised by sub-groups of unequal size, the Kruskal-Wallis test was applied to assess statistical significance, with Dunn's post-hoc pairwise comparison (adjusted by the Holm FWER method) used to determine where significant differences were present. Results were reported as p-values and considered statistically significant at the standard 5% level. Multivariate regression analysis using a generalised linear model (GLM) was performed to estimate conditional mean health expenditure and identify covariates associated with increased healthcare utilisation. Because several prior studies have demonstrated that the gamma family with a log error link is not only robust, but also the most commonly applied approach in healthcare cohorts in which positive and skewed healthcare costs are guaranteed, <sup>23, 24</sup> our analysis also assumed a gamma error distribution with log-link. Finally, because all timings employed within the TDABC were estimates, and therefore subject to one or more of (1) sampling bias, (2) Hawthorne effects, or (3) reporting bias, a distribution of credible times for each patient interaction with healthcare personnel was used in the time-driven and activity-based costing, to reflect the uncertainty inherent to sampling. For all parameters

contained within the time-driven and activity-based costing, continuous variables (time in consultation with clinician, days spent as inpatient) were randomly sampled from gamma distributions as explained by Briggs.<sup>25</sup> Dichotomous variables (percentage of triage assessments performed by band 5/6 nurses) were sampled from representative beta distributions constructed from the sample data available, as explained in previous work by Briggs et al <sup>26</sup>. For estimates reliant on expert opinion, which were not observed during the time-in-motion study due to a low frequency of occurrence, uniform distributions were sampled in absence of information concerning the true sample mean and variance. In choosing this distribution we combined and ranked response data from all healthcare professionals (of varying roles and experience) surveyed, to define lower and upper limits or 'bounding' criterion. Once responses were provided, respondents were informed of responses by other respondents to gauge their belief in the credibility of different responses and ensure that the distributions utilized were plausible. GLM regression modelling was subsequently replicated for 100 bootstrapped costing datasets randomly utilizing parameter values from all plausible distributions, for all variables; to assess the sensitivity of the primary outcome, the cost per febrile illness episode, and the resulting GLM coefficients, to changes in the values of underlying input parameters. Details of all distributions utilized are provided in Table S2. All analyses were performed using STATA 14 (StataCorp LP, USA) and Microsoft® Excel<sup>TM</sup>, (Redmond, WA).

342

343

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

Table S2: Distributions used for probabilistic sensitivity analysis

| PARAMETER                             | DISTRIBUTION       |
|---------------------------------------|--------------------|
| TIME (HOURS)                          |                    |
| Nurse triage                          | Gamma (4.69, 0.01) |
| Proportion performed by band 6 nurses | Beta (16,55)       |
| Proportion performed by band 5 nurses | 1- Beta (16,55)    |
| Clinical consultation                 | Gamma (3.9, 0.04)  |
| Clinician writing up patient notes    | Uniform (1,20)     |
| Arrange blood/urine culture           | Uniform (1,25)     |
| Arranging X-ray                       | Uniform (1,30)     |
|                                       |                    |

| Receptionist booking patient in       | Uniform (1,5)         |
|---------------------------------------|-----------------------|
| Clinician arranging referral          | Uniform (1,25)        |
| Clinician cannulating child           | Uniform (5,35)        |
| Nurse providing antibiotics to child  | Uniform (1,10)        |
| Visual assessment by nurse            | Uniform (0.5,5)       |
| Days spent as inpatient (if admitted) | Gamma (3.72, 1.03)    |
| SALARY (COST/HOUR)                    |                       |
| Nurse (band 5)                        | Uniform (13.36,17.5)  |
| Nurse (band 6)                        | Uniform (16.14,21.77) |
| Nurse (band 7)                        | Uniform (19.34,25.67) |
| Nurse (band 8a)                       | Uniform (24.8,29.99)  |
| Foundation year doctor                | Uniform (22.5,26)     |
| ST1-3                                 | Uniform (27, 30.8)    |
| APNP                                  | Uniform (24.8,29.99)  |
| Registrar                             | Uniform (36,41)       |
| Consultant                            | Uniform (64.8,87.4)   |

# **RESULTS**

### Descriptive statistics

8,552 individual ED attendances were identified over the study period, with 2,034 excluded from the analysis due to incomplete data or failing to meet our inclusion criteria. This resulted in a complete dataset of 6,518 observations (Table 2). There was no significant difference in observable characteristics between those included and excluded; including but not limited to age, final diagnoses, MTS classification and temperature.

Table 2: Descriptive statistics of study participants

The mean (median) age of children included was 3.28 (2.17) years, with 53.5% male and 46.5% female. At presentation, 47.52% of children were triaged as green 'low risk' cases using the Manchester Triage System (MTS), 17 8.88% as yellow, 0.17% as yellow/red, 17.06% as orange, 23.03% as orange/red and 0.39% as red (high risk). MTS classifications were not recorded in 2.9% of patients. Most patients (66.32%) were treated by specialty doctors (ST1-3), followed by registrars or ST4-8 (22.05%), consultants (7.99%), APNPs (2.73%), and Foundation year 1 & 2 doctors (0.91%). The mean (median) time was 15.3 (14.7 mins) between booking and triage, 67.9 (52 mins) between triage and clinical consultation, and 68.4 (70.6 mins) between consultation and discharge. Total mean (median) time in the ED was 151.6 mins (81.3 mins). Approximately 6.46% of patients were admitted as inpatients, 1.42% of which for a single day, 29.78% (two days), 21.51% (three days), and 47.28% (> four days).

### Determinants of patient-level costs

Table 3 provides details of patient-level resource use and costing. Those aged 0-3 months exhibited a mean treatment cost of £1000.28, [95% CI £82.89-£2.993.37], over 6-fold higher than the least costly group, aged 3-6 years, (£158.97, [95% CI £20.43-£1,596.43]). Use of blood cultures (p=0.0312), urine samples, inpatient admission rates, and inpatient length of stay (p=0.0001) were all statistically significantly increased for those aged 0-3 months, versus all other age groups, as shown in Table 4.

Table 3: Health service costs of paediatric febrile illness by sub-group

|          | INPATIE     | LEN<br>GTH<br>OF | AN<br>Y | BLOO<br>D   | X-<br>RA | URIN<br>E  | REVIEW<br>BY   |  |
|----------|-------------|------------------|---------|-------------|----------|------------|----------------|--|
|          | NT          | STAY<br>(DAY     |         | CULT<br>URE | Y        | SAM<br>PLE | CONSULTA<br>NT |  |
|          |             | <b>S</b> )#      |         |             |          |            |                |  |
| AGE      |             |                  |         |             |          |            |                |  |
| 0-3      |             |                  | 51.1    |             | 9.30     | 39.53      | 10.07%         |  |
| months   | 34.11%      | 5.67             | 6%      | 28.70%      | %        | %          | 10.0770        |  |
| 3-6      |             |                  | 40.9    |             | 12.1     | 32.74      | 5.69%          |  |
| months   | 15.66%      | 5.34             | 2%      | 11.03%      | 0%       | %          | 3.09%          |  |
| 6-12     |             |                  | 31.9    |             | 9.12     | 23.24      | 0.740/         |  |
| months   | 6.34%       | 3.83             | 8%      | 2.01%       | %        | %          | 8.64%          |  |
| 1-3      |             |                  | 29.7    |             | 10.8     | 18.37      | <b>5</b> (40)  |  |
| years    | 5.36%       | 4.05             | 4%      | 2.52%       | 8%       | %          | 7.64%          |  |
| 3-6      |             |                  | 28.7    |             | 9.43     | 13.70      | 0.140/         |  |
| years    | 4.01%       | 4.02             | 0%      | 3.03%       | %        | %          | 8.14%          |  |
| 6-10     |             |                  | 34.0    |             | 9.61     | 17.25      |                |  |
| years    | 4.53%       | 3.78             | 8%      | 3.67%       | %        | %          | 8.76%          |  |
| 10-16    |             |                  | 42.2    |             | 10.1     | 15.87      |                |  |
| years    | 7.96%       | 4.73             | 2%      | 8.88%       | 5%       | %          | 7.3%           |  |
|          |             | 0.0001           | 0.00    |             | 0.53     | 0.0001     |                |  |
| P-value  | 0.0001§     | *                | 01§     | 0.0001§     | 70§      | §          | 0.1342§        |  |
| MTS CLAS | SSIFICATION |                  |         |             |          |            |                |  |
|          |             |                  | 24.5    |             | 5.68     | 16.17      | 0.070/         |  |
| Green    | 2.61%       | 3.88             | 9%      | 1.51%       | %        | %          | 8.06%          |  |
|          |             |                  | 43.5    |             | 11.9     | 23.48      | 0.222/         |  |
| Yellow   | 13.64%      | 4.64             | 2%      | 7.42%       | 1%       | %          | 9.32%          |  |

|         |               |        | 44.6 |               | 23.2 | 19.15  | 8.45%   |
|---------|---------------|--------|------|---------------|------|--------|---------|
| Orange  | 17.27%        | 4.23   | %    | 10.07%        | %    | %      | 0.4370  |
|         |               |        | 26.9 |               | 11.5 | 11.53  | 22.070/ |
| Red     | 30.77%        | 2.63   | 2%   | 15.38%        | 3%   | %      | 23.07%  |
|         |               | 0.0001 | 0.00 |               | 0.00 | 0.0023 |         |
| P-value | $0.0001^{\S}$ | #      | 01§  | $0.0001^{\S}$ | 01§  | §      |         |

<sup>#</sup> Mean length of stay among those admitted for at least one day

The distribution of MTS classifications was approximately equal across all age-groups, except for those aged 0-3months, 74.41% of which were triaged as yellow or higher. As expected, overall healthcare expenditure increased with increasing MTS severity, from £121.78 per patient (green), £424.43 (yellow), £487.16 (orange), and £549.42 (red); the majority of which as a direct result of increasing rates of inpatient admission. A one-step increase in triage category, from green to yellow, resulted in a 422% increase in inpatient admission, a 19.6% increase in length of stay for those admitted, and a 391% increase in use of blood cultures. In terms of final diagnoses, bacterial infections were most commonly observed in those aged 0-3 months (15.5%), 3-6months (11.03%) and 10-16 years (11.74%), however the only significant difference was when comparing these groups to those aged 1-3 years (4.6%), p<0.05. Those with bacterial aetiologies of fever

exhibited over 3-fold higher management costs than those with viral aetiologies (£988.19 vs.

### Antibiotic prescribing patterns

£294.52).

Approximately 32.4% of febrile children were prescribed antibiotics, of whom 7.05% were retrospectively diagnosed with bacterial aetiologies of fever. Approximately 14.9% of patients

<sup>\*</sup>Kruskal-Wallis test

<sup>§</sup> Chi-squared test

retrospectively classified as having inflammatory, 10.8% as trivial, and 6.6% as viral aetiologies of fever (probable, definite and viral syndromes), were prescribed potentially avoidable antibiotics, if a means of distinguishing these from bacterial causes of infection been available. Analysing children with viral causes of fever who were triaged as MTS green or yellow (those not deemed to require very urgent or immediate care); those receiving antibiotics spent an additional 53.9 hours as inpatients (57.1 vs. 3.2hours) compared to children with viral aetiologies of fever, triaged MTS green or yellow, who were not prescribed antibiotics. This resulted in a 9.9-fold increase in management costs for those who received potentially avoidable antibiotics (£1,392.30 vs. £140.10) as shown in Table 5b; the majority of which attributable to the costs of inpatient or short stay beds for observation.

Table 5a: Antibiotic prescribing rates differentiated by age and final diagnosis

| RECEIVING ANTIBIOTICS |       |        |        |        |       |       |   |
|-----------------------|-------|--------|--------|--------|-------|-------|---|
|                       |       | 0-3    | 3-6    | 6-12   | 1-3   | 3-6   |   |
|                       | TOTAL | MONTHS | MONTHS | MONTHS | YEARS | YEARS | • |
| All                   | 32.4% | 27.9%  | 24.2%  | 24%    | 31.9% | 37%   |   |
| Bacterial             | 89.6% | 85%    | 96.8%  | 84.3%  | 93%   | 89%   |   |
| Viral                 | 6.6%  | 20.8%  | 10%    | 3.2%   | 9.4%  | 4%    |   |
| Inflammatory          | 14.9% | 0%     | 0%     | 0%     | 9.5%  | 17.2% |   |
| Trivial               | 10.8% | 0%     | 50%    | 0%     | 9.7%  | 8.1%  |   |
| Unknown               | 36.4% | 17.3%  | 19.2%  | 25.5%  | 35.7% | 43.3% |   |

Table 5b: Treatment costs differentiated by age, final diagnosis and antibiotic status

|                    | VIRAL     |         | TRIVIAL   |         | INFLAM  | IMATORY   |
|--------------------|-----------|---------|-----------|---------|---------|-----------|
| ANTIBIOTICS GIVEN? | YES       | NO      | YES       | NO      | YES     | NO        |
| All*               | £1,392.30 | £140.10 | £324.49   | £224.54 | £185.08 | £669.86   |
| 0-3 months         | £2,842.60 | £479.65 | N/A       | £113.81 | N/A     | £50.87    |
| 3-6 months         | £1,969.38 | £142.81 | £50.39    | £334.50 | N/A     | £65.92    |
| 6-12 months        | £2,452.83 | £159.57 | N/A       | £58.63  | N/A     | N/A       |
| 1-3 years          | £687.02   | £151.09 | £2,223.43 | £256.88 | £51.43  | £390.81   |
| 3-6 years          | £1,201.76 | £123.97 | £58.69    | £196.88 | £54.52  | £355.06   |
| 6-10 years         | £1,575.80 | £63.65  | £51.46    | £87.65  | £475.93 | £447.47   |
| 10-16 years        | £2,603.54 | £143.37 | N/A       | £401.88 | £101.95 | £4,842.32 |

\*MTS green and yellow only

### Determinants of increased healthcare expenditure during paediatric febrile episodes

Based on generalized linear modelling, compared to the reference group of those aged 1-3years, those aged 0-3 months, experienced a 3.54-fold [95% CI 2.59-4.85-fold, p<0.0001] increase in healthcare resource use. The presence of a NICE NG51 respiratory rate red flag,<sup>27</sup> increased costs by 72.1% (p<0.0001) (Table 6). Other factors associated with increased resource use included treatment by FY1/FY2 doctors, which were increased 3.19-fold, relative to the consultant reference group, p<0.0001. When considering only non-urgent children, triaged as Green using the MTS, FY1/FY2 doctors exhibited a 7.98-fold increase in costs of management, relative to consultants (p<0.0001). FY1/FY2 doctors recorded the highest rates of inpatient admission, ancillary investigations, and referring children to other specialties. Comparing resource use for FY1/FY2 doctors working out-of-hours and those working during regular hours, where the availability of ancillary investigations may be reduced, there was no significant difference (p=0.9626). Factors including male gender, and being treated by an APNP, were shown to reduce costs by 15.1% (p=0.0241), and 42.7% (p=0.0112) respectively.

Table 6: Determinants of healthcare resource use for paediatric febrile episodes

Increasing clinical severity, as proxied by increasing MTS classifications, resulted in significant cost increases of 138.2% (2.38-fold), 185.7% (2.85 fold) and 199.2% (2.99-fold) respectively compared to children triaged as green, (all p<0.01). As such, we performed independent GLM regressions for three MTS groups (green, yellow and orange/red), to account for the possibility that severity of illness may have an important role in determining overall resource use. Similar to the results when pooling children of all severities, those demonstrated in Figure 2 highlight the consistent importance of ages (<6 months, 10-16 years), prompting a NICE respiratory rate red flag <sup>27</sup>, and being treated by an FY1 or FY2 doctor, suggesting that these are key drivers of increased resource use when managing paediatric febrile illness after taking clinical severity into account.

Figure 2: Determinants of healthcare resource use among febrile children of differing clinical risk/urgency

### Sensitivity analysis

Our findings were insensitive to changes in the values of our input parameters. Following Monte Carlo simulation and re-running our generalized linear models on 100 bootstrapped datasets, the coefficients listed in Table 7 were obtained. Children triaged as MTS Yellow or above, those prompting a NICE NG51 respiratory rate red flag, those treated by an FY1/FY2 doctor, and treatment of children aged 0-3 months, 3-6 months or 10-16 years respectively, were statistically significant predictors of increased healthcare costs in 100% of simulations. Conversely, the cost savings associated with male gender and treatment by an APNP, remained significant in just 8% and 28.3% of simulations respectively.

Table 7: Sensitivity analyses of determinants of healthcare costs for paediatric febrile episodes

## **DISCUSSION**

This study reports the largest comprehensive, prospective observational study to date, assessing the economic implications of diagnostic uncertainty when managing paediatric febrile illness, in those aged 0-16 years, in an ED setting. In a full cohort analysis on the management of this highly common condition, we demonstrate that the healthcare resources required to manage this condition are both significant and subject to extensive variation, some of which can be explained by the presence of certain patient and healthcare provider characteristics. Infants aged 0-6 months (particularly those aged 0-3 months), those triaged as MTS yellow or above, and those managed by lesser experienced clinicians (FY1 and FY2), required significantly greater resources in the ED. This was primarily a result of increases in observation time for patients and inpatient length of stay, the latter particularly prominent in those receiving antibiotics. In cases of MTS green and yellow viral infections, where antibiotics were potentially avoidable had more sensitive and prompt diagnostics been available at this time, costs increased 9.9-fold (95% CI 6.48-13.2-fold). This was equivalent to an additional £1,352.20 spend per patient (all patients pooled), rising to £2,363 for infants aged less than three months.

Our study had several strengths. We included more than 6,500 febrile children over all seasons during a one-year period, and by applying TDABC methodology we could achieve significant detail regarding actual resource use. This resulted in an inclusive and representative estimate of the economic impact of paediatric febrile illness to NHS EDs. Capturing model input data using a prospective time-in-motion approach provided confidence regarding the time requirements of essential components of care in the patient pathway. Data regarding these patient touchpoints are not currently available in published literature, and we believe this analysis has filled a gap which may subsequently be used for similar health-economic analyses in the future.

Limitations of our study include the fact that presumed viral and bacterial aetiologies of fever were applied retrospectively, therefore we lacked the benefit of clinical acumen and parental anxiety which could heavily influence the decision to prescribe antibiotics. While we made every effort to minimize bias when coding final diagnoses using the algorithm provided by Herberg et al. 18 there is a possibility that errors could have occurred, which may have affected conclusions regarding potentially avoidable antibiotics in the event of an incorrect diagnosis. However, following random sampling and checking of diagnoses we believe the likelihood of this to be minimal given the level of detail provided and simplicity in using the diagnosis algorithm. Another potential limitation is the completeness of the dataset, with just under 24% of observations removed due to missing or incomplete data. While it was assumed that these data were missing at random, we cannot be sure of this, and as such we are unsure how the results may have differed if data for these 2,034 children were available. While we made every effort to ensure a thorough approach to capturing NHS resource use, there were also instances where we likely underestimated costs. Our time-in-motion data did not capture information regarding additional consultations and advice from senior members of staff, which are likely to increase the costs of lesser experienced clinicians managing febrile children; nor did it include the societal costs of febrile illness borne by parents, including time off work, especially in the case of hospitalisation. Considering that new diagnostics may result in a reduction in antibiotic use, it is plausible that reattendances or time observing patients in the department could increase, thereby potentially reducing the value to parents of improved diagnostics. The final limitation of our study concerns the generalizability of the findings to other settings, whether in the United Kingdom, Europe or further afield. Our data were collected from a single site, and our analysis based on local prescribing protocols, as such, the economic value of improving the management of febrile illness in other settings, including the United States, where are a more consultantled approach may be more common, may differ from those demonstrated here.

526

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

Two previous studies have reported healthcare costs for managing children with SBIs, namely UTI, <sup>13</sup> and meningitis. <sup>14</sup> Two studies reporting costs of management for children with fever of any cause, <sup>15,16</sup> have been performed in the USA, with data collected at least 5 years ago, in children aged <3 years and <90 days respectively, thereby limiting their generalisability. Additionally, one study conducted in Switzerland demonstrates the cost-of-illness associated with paediatric community acquired pneumonia in 2010 <sup>28</sup>. However, no study prior to ours has assessed the resource implications of managing fever in a broad and representative cohort of all ages, diagnoses, and types of resource use in Europe.

The finding that infants (particularly those aged <3months) tended to require significantly greater ED resources, may be explained by increased cautiousness, and a lack of symptomatic information directly from the children themselves, when managing febrile infants. Despite most causes of fever in children being self-limiting, the fear of missing life-threatening infection in children with fever remains a persistent problem for clinicians, who have a natural tendency to be risk-averse. Commonly reported concerns among clinicians treating febrile children include suspected central nervous system damage (24%), seizures (19%), and death (5%), manifesting in overly aggressive, and often, in hindsight, unnecessary treatment. Additionally, the prevalence of invasive bacterial infections, bacteraemia and bacterial meningitis, are highest in the first 3 months of life, driving clinician behaviour towards a cautious approach in this high-risk group. Clinical prediction rules, such as the Yale observation scale may be useful in these groups, particularly among those with less experience in ruling in/out serious bacterial infections; however, reliability in higher vs. lower income countries is variable, suggesting that these alone, may not be enough to fill the diagnostic gap faced by the clinician managing paediatric febrile illness.

Though potentially avoidable antibiotic prescribing was lower in our cohort (6.6% viral, 10.8% trivial illness) than in similar studies based in the United States (36%),<sup>35</sup> and Oxford, England

(34%) <sup>36</sup>, we found that antibiotic prescribing for those with viral causes of fever was highest in those aged 0-3 (20.8%), and 3-6 months (10%) supporting our finding of an increased tendency to be cautious when treating young febrile infants. This resulted not only in a substantial increase in ED resource use, but also likely increased inconvenience and distress to the children and parents involved, due to potentially unnecessary investigations and treatment. Furthermore, excess use of antibiotics is known to contribute to increasing rates of antimicrobial resistance (AMR),<sup>37</sup> an important component of both the clinical and economic impact of AB prescribing which we were unable to quantify in this analysis.

Given the paucity of published evidence, additional research examining the patient-centred and societal implications of current diagnosis and treatment practices when managing the febrile child, would add considerable value for those looking to determine the true value of improved diagnostics, which may be capable of better targeting of scarce ED resources. Given the variable performance and accuracy of the MTS triage system in paediatric populations, we believe our finding that costs increased with MTS severity is noteworthy. Recent large-scale validation studies have highlighted the low reliability of the MTS in both younger, <sup>17</sup> and older children presenting to the ED with fever, 38 with an estimated 54% of children over-triaged when using the MTS.<sup>34</sup> In adult studies, over-triaging by just a single category, from green to yellow, has been shown to increase the use of electrocardiogram (ECG) and laboratory investigations by 261% and 148% respectively.<sup>39</sup> Similarly, in our study, children triaged as yellow experienced a 422% increase in inpatient stay, a 76.9% increase in ancillary investigations, and a 15.6% increase in review by consultants, versus those triaged as green. As the MTS categories yellow, orange and red represent urgent, very urgent and immediate attention respectively, these are the groups with the highest probability of SBIs, we believe these are the groups where novel diagnostics should be targeted.

While we found evidence of an increase in healthcare utilisation among the least experienced clinicians (FY1/FY2), just 0.9% of clinicians included in our study were FY1 and FY2 doctors. The results observed in this sample were therefore highly susceptible to bias through a lack of

inter-clinician variability, and with a larger sample size may regress towards a lower mean. Additionally, although GLM analyses highlighted a 44.2% increase in time spent in the ED for those treated by FY1 and FY2 doctors when compared to consultants, this was likely due to the need to seek second opinions from more experienced colleagues, something which we were unable to attach costs to. This may also have been because lower acuity patients wait the longest and are more likely to be seen by lesser experienced doctors, as the sickest are re-directed to senior doctors. Because it is likely that any advances in diagnostics are likely to be heavily used by lesser experienced doctors, this could reduce times in the ED, but potentially still increase management costs. This is particularly true if the price of novel POC tests is high, as with multiplex PCR, which may cost the same as a day in hospital when first released. The price of such tests can however be expected to decrease over time, resulting in savings over the longer-term.

## CONCLUSIONS

In conclusion, based on a comprehensive and representative sample of febrile children of varying age, presenting complaints, final diagnoses and treating clinicians, this study has shown that the management of paediatric febrile illness in the ED poses a substantial financial burden. This is predominantly due to impact of diagnostic uncertainty, that most often leads to in increased observation time and inpatient admission. Children aged 0-6 months, those triaged as MTS yellow and above, and those managed by newly qualified doctors are the most likely to receive additional resources in the ED. After accounting for the severity of illness, precautionary antibiotic prescribing, particularly in younger low acuity children with viral illnesses, is associated with substantial increases in health service utilization, predominantly because of increases in inpatient admissions. So far, information on potential shifts in infection epidemiology, such as an increase in health care-associated infections or reductions in vaccine –preventable infections or increases in invasive disease due to serotype replacement are unlikely to affect our conclusions.

Comparable settings in the United Kingdom and elsewhere will likely show similar patterns in resource use. Any advances in diagnostic capabilities, including molecular diagnostics, protein

| 613 | biomarkers and POC tests would likely yield the potentially greatest efficiency gains in these |   |  |  |  |  |
|-----|--|---|--|--|--|--|
| 614 | groups of children, as among these the perceived risks of untimely diagnosis are greatest.     |   |  |  |  |  |
| 615 |  |   |  |  |  |  |
| 616 |  |   |  |  |  |  |
| 617 | ABBR   | EVIATIONS   |  |  |  |  |
| 618 | 95% CI   | 95% Confidence interval                           |  |  |  |  |
| 619 | AB   | Antibiotic  |  |  |  |  |
| 620 | AOM  | Acute otitis media                                |  |  |  |  |
| 621 | APNP   | Advanced paediatric nurse practitioner            |  |  |  |  |
| 622 | CRP  | C-reactive protein                                |  |  |  |  |
| 623 | ECG  | Electro cardiogram                                |  |  |  |  |
| 624 | ED   | Emergency department                              |  |  |  |  |
| 625 | FY1/FY2  | Foundation year 1/ foundation year 2              |  |  |  |  |
| 626 | GLM  | Generalised linear model                          |  |  |  |  |
| 627 | IQR  | Interquartile range                               |  |  |  |  |
| 628 | MTS  | Manchester triage system                          |  |  |  |  |
| 629 | NHS  | National health service                           |  |  |  |  |
| 630 | NICE   | National institute for health and care excellence |  |  |  |  |
| 631 | POC  | Point of care                                     |  |  |  |  |
| 632 | SBI  | Serious bacterial infection                       |  |  |  |  |
| 633 | SD   | Standard deviation                                |  |  |  |  |
| 634 | ST1-3  | Specialised training years 1-3                    |  |  |  |  |
| 635 | TDABC  | Time-driven and activity-based costing            |  |  |  |  |
| 636 | USA  | United States of America                          |  |  |  |  |
| 637 | UTI  | Urinary tract infection                           |  |  |  |  |
| 638 |  |   |  |  |  |  |

# **DECLARATIONS**

640 Ethics approval and consent to participate Ethical approval was the study was granted by North West 9 Research Ethics Committee 641 642 REC reference number: 10/H1014/53. 643 Consent for publication 644 Not applicable 645 646 647 Availability of data and materials 648 The data that support the findings of this study are available from the authors upon 649 reasonable request. 650 651 Competing interests 652 The authors declare that they have no competing interests 653 654 Funding 655 SL is funded by a studentship from the Institute of Infection and Global Health, The University of 656 Liverpool and the European Union's Horizon 2020 research and innovation programme under 657 grant agreement No. 668303 (PERFORM study (Personalised Risk assessment in Febrile illness 658 to Optimise Real-life Management across the European Union). The study sponsors had no 659 involvement in the formation of the research questions nor the analysis itself. 660 661 Authors' contributions EDC and LN devised the study and will act as guarantors for the paper), AG supervised collection 662 of data, EH, NM, LH, JBM, NMOC, YR, SS, SD and HD helped collect data. SL, BF and FC 663 664 planned and performed all statistical analyses, with SL conducting all costings and data cleaning. 665 JD collected costing data and KE collected additional electronic patient data. SL wrote the first

| 666 | draft of the manuscript and revised and approved the final manuscript as submitted. All authors |
|-----|---|
| 667 | helped draft the manuscript and approved the final submitted version.                           |
| 668 |   |
| 669 | Acknowledgements  |
| 670 | We thank the children and their parents for participating in the study, and ED staff for their  |
| 671 | considerable contribution to the study.   |
| 672 |   |
| 673 | REFERENCES  |
| 674 | [1] Krauss BS, Harakal T, Fleisher, GR. The spectrum and frequency of illness presenting to a   |
| 675 | pediatric emergency department," Pediatr Emerg Care 1991; 7(2): 67-71.                          |
| 676 | [2] Alpern ER, Henretig FM. Fever. Fleisher GR, Ludwg S, Textbook of paediatric emergency       |
| 677 | medicine. 5th edition, Philadelphia 2006; 295–306,  |
| 678 | [3] Limper M, Eeftinck Schattenkerk D, de Kruif MD, van Wissen M, Brandjes DP, Duits AJ, et     |
| 679 | al. One-year epidemiology of fever at the emergency department, Netherlands J Med 2011; 69      |
| 680 | (3): 124–8.   |
| 681 | [4] Irwin, AD, Drew, RJ, Marshall, P, et al. Etiology of childhood bacteremia and timely        |
| 682 | antibiotics administration in the emergency department. Pediatrics 2015; 135, 4:635-42.         |
| 683 | [5] Gangoiti, I, Rodriguez, E, Zubizarreta, et al. Prevalence of Occult Bacteremia in Infants   |
| 684 | With Very High Fever Without a Source. Pediatr. Infect. Dis. J, 2018; 37, 11                    |
| 685 | [6] Irwin, AD, Grant, A, Williams, R, et al. Predicting Risk of Serious Bacterial Infections in |
| 686 | Febrile Children in the Emergency Department. Pediatrics, 2017; 140, 2                          |
| 687 | [7] Mejer, N, Westh, H, Schønheyder, HC, et al. Stable incidence and continued improvement in   |
| 688 | short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect.    |
| 689 | Dis 2012; 12:260.   |
| 690 | [8] Ladhani S, Pebody RG, Ramsay ME, et al. Continuing impact of infectious diseases on         |
| 691 | childhood deaths in England and Wales, 2003-2005. Pediatr Infect Dis J. 2010; 29(4):310-313     |
| 692 | [9] Wright C, Wordsworth R, Glennie L. Counting the cost of meningococcal disease: Scenarios    |
| 693 | of severe meningitis and septicemia, Paediatr Drugs 2013; 15 (1):49-58                          |
|     |   |

- Nijman RG, Vergouwe Y, Thompson M, van Veen M, van Meurs AH, van der Lei J,
- et al. Clinical prediction model to aid emergency doctors managing febrile children at risk of
- serious bacterial infections: diagnostic study, BMJ 2013; 346: f1706
- Martinón-Torres F, Salas A, Rivero-Calle I, et al. EUCLIDS Consortium. Life-
- threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study.
- 699 Lancet Child Adolesc Health. 2018 Jun; 2(6):404-414.
- Weddle G, Jackson MA, Selvarangan R. Reducing blood culture contamination in a
- pediatric emergency department, Pediatr Emerg Care 2011; 27 (3):179–81
- Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, et al. Oral
- versus initial intravenous therapy for urinary tract infections in young febrile children, Pediatrics
- 704 1999; 104 (1): 79–86
- 705 [14] Bell JM, Shields MD, Agus A, Dunlop K, Bourke T, Kee F, et al. Clinical and Cost-
- 706 Effectiveness of Procalcitonin Test for Prodromal Meningococcal Disease-A Meta-Analysis,
- 707 PLoS One 2015; 10 (6): e0128993.
- 708 [15] Byington CL, Reynolds CC, Korgenski K, Sheng X, Valentine KJ, Nelson RE, et al.
- Costs and infant outcomes after implementation of a care process model for febrile infants,
- 710 Pediatrics 2012; 130 (1) e16-24
- 711 [16] Schriger DL, Baraff LJ, Buller K, Shendrikar MA, Nagda S, Lin EJ, et al.
- Implementation of clinical guidelines via a computer charting system: effect on the care of febrile
- 713 children less than three years of age, J Am Med Inf. Assoc 2000; 7(2): 186–95
- 715 [17] Zachariasse JM, Seiger N, Rood PPM, Alves CF, Freitas P, Smit FJ, et al. Validity of
- the Manchester Triage System in emergency care: A prospective observational study, PLoS One
- 717 2017;12(2): e0170811

- 718 [18] Herberg JA, Kaforou M, Wright VJ, Shailes H, Eleftherohorinou H, Hoggart CJ, et
- al. Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial
- vs Viral Infection in Febrile Children, JAMA 2016; 316 (8):835–45

- 721 [19] Elfving K, Shakely D, Andersson M, Baltzell K, Ali AS, Bachelard M, et al. Acute
- Uncomplicated Febrile Illness in Children Aged 2-59 months in Zanzibar Aetiologies, Antibiotic
- 723 Treatment and Outcome.," PLoS One 2016; 11: 1:e0146054
- 724 [20] NHS Employers: Unsocial hours payments Section 2(a) (England), 2017. Available
- at: http://www.nhsemployers.org/your-workforce/pay-and-reward/agenda-for-change/nhs-terms-
- and-conditions-of-service-handbook/unsocial-hours-payments. Accessed 8th August 2017
- 727 [21] Gov.uk NHS Reference Costs 2015/16. 2016. Available:
- https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016. Accessed 11th
- 729 April 2017
- 730 [22] NICE CG160: Fever in under 5s: Assessment and initial management, 2017
- Hardin JW, Hilbe JM. Generalized Linear Models and Extensions. 2nd Stata Press;
- 732 College Station (TX): 2007.
- 733 [24] Manning WG, Basu A, Mullahy J. Technical working paper 293: Generalized
- modelling approaches to risk adjustment of skewed outcomes data. In: National bureau of
- economic research, technical working paper series. 2003. http://www.nber.org/papers/T0293.
- 736 Accessed 18 Feb 2016.
- 737 [25] Briggs, AH. Probabilistic analysis of cost-effectiveness models: statistical
- representation of parameter uncertainty. Value in Health. 2005; 8(1)
- 739 [26] Briggs A, Sculpher M, Claxton K. Decision modelling for health economic
- 740 evaluation. 3rd ed. Oxford 2006.
- 741 [27] NICE NG51: Sepsis: recognition, diagnosis and early management, 2017
- Keitel, K, Alcoba, G, Lacroix, L, Manzano, S, Galetto-Lacour, A, Gervaix, A.
- Observed costs and health care use of children in a prospective cohort study on community-
- acquired pneumonia in Geneva, Switzerland. Swiss Med Wkly. 2014;144.
- Gunduz S, Usak E, Koksal T, Canbal M. Why Fever Phobia Is Still Common?, Iran
- 746 Red Crescent Med J 2016; 18 (8): e23827
- 747 [30] Crocetti M, Moghbeli N, Serwint J. Fever phobia revisited: have parental
- misconception about fever changed in 20 years? Pediatrics 2001; 107 (6): 1241–6

- [31] Elkon-Tamir E, Rimon A, Scolnik D, Glatstein, M. Fever Phobia as a Reason for
- Pediatric Emergency Department Visits: Does the Primary Care Physician Make a Difference?
- Rambam Maimonides Med J 2017; 8 (1)
- Nigrovic, LE, Mahajan, PV, Blumberg, SM, et al. The Yale Observation Scale Score
- and the Risk of Serious Bacterial Infections in Febrile Infants. Pediatrics, 2017; 140: np
- Bang, A, Chaturvedi, P. Yale Observation Scale for prediction of bacteremia in
- 755 febrile children. Indian J Pediatr 2009; 76, 6:599-604.
- 756 [34] Thompson, M, Van den Bruel, A, Verbakel, J. Systematic review and validation of
- prediction rules for identifying children with serious infections in emergency departments and
- 758 urgent-access primary care. Health Technol Assess, 2012; 16, 15:1-100.
- 759 [35] Wilkes JJ, Leckerman KH, Coffin SE, Keren R, Metjian TA, Hodinka RL. Use of
- antibiotics in children hospitalized with community-acquired, laboratory-confirmed influenza., J
- 761 Pediatr 2009; 154 (3): 447–9
- Harnden, A, Perera, R, Brueggemann, AB, Mayon-White, R, Crook, DW, Thomson,
- A, et al. Respiratory infections for which general practitioners consider prescribing an antibiotic:
- 764 a prospective study. Arch. Dis. Child. 2007; 92, 7: 594-7.
- Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global
- prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli
- and association with routine use of antibiotics in primary care: systematic review and meta-
- 768 analysis," BMJ 2016; 352: i939
- van Veen M, Steverberg EW, Ruige M, van Meurs AH, Roukema J, van der Lei J, et
- al. Manchester triage system in paediatric emergency care: prospective observational study, BMJ
- 771 2008; 337: a1501
- 772 [39] Santos AP, Freitas P, Martins HM, Manchester Triage System version II and resource
- utilisation in the emergency department, J Emerg Med 2014; 31 (2): 148–52

# 779 <u>TABLES</u>

Table S1: Unit costs by component of paediatric febrile illness pathway

| ITEM                      | UNIT COST |  |  |  |
|---------------------------|-----------|--|--|--|
| INVESTIGATIONS (PER TEST) |           |  |  |  |
| Amylase                   | £6.00     |  |  |  |
| Bacterial PCR             | £158.00   |  |  |  |
| Bilirubin                 | £6.00     |  |  |  |
| Biochemistry Profile      | £8.00     |  |  |  |
| Blood albumin             | £6.00     |  |  |  |
| Blood glucose test        | £6.00     |  |  |  |
| Blood Culture             | £35.00    |  |  |  |
| Blood gas #               | £7.00     |  |  |  |
| Blood taken               | £3.00     |  |  |  |
| Calcium profile           | £7.00     |  |  |  |
| Clotting screen           | £5.00     |  |  |  |
| Creatinine                | £6.00     |  |  |  |
| CRP                       | £6.00     |  |  |  |
| CSF                       | £6.00     |  |  |  |
| CT scan (Head)            | £201.00   |  |  |  |
| ECG                       | £33.00    |  |  |  |
| ENT Swab                  | £19.00    |  |  |  |
| ESR                       | £4.00     |  |  |  |

| FBC                             | £3.00   |  |  |  |  |
|---------------------------------|---------|--|--|--|--|
| Glandular fever screen          | £4.00   |  |  |  |  |
| Group and save                  | £12.00  |  |  |  |  |
| LFTs                            | £7.00   |  |  |  |  |
| Magnesium                       | £6.00   |  |  |  |  |
| Malarial parasites test         | £21.00  |  |  |  |  |
| Measles PCR                     | £55.00  |  |  |  |  |
| Meningo pneumo PCR              | £25.00  |  |  |  |  |
| Meningococci screen             | £6.00   |  |  |  |  |
| Mycoplasma SER                  | £23.00  |  |  |  |  |
| Pertussis swab                  | £9.00   |  |  |  |  |
| Phosphate                       | £6.00   |  |  |  |  |
| Rapid Strep Test                | £9.00   |  |  |  |  |
| Renal profile                   | £46.00  |  |  |  |  |
| Respiratory PCR                 | £117.00 |  |  |  |  |
| RSV screen                      | £12.00  |  |  |  |  |
| Ultrasound                      | £55.00  |  |  |  |  |
| Urinalysis #                    | £8.00   |  |  |  |  |
| Urine albumin                   | £6.00   |  |  |  |  |
| Urine culture #                 | £8.00   |  |  |  |  |
| Urine dipstick #                | £6.00   |  |  |  |  |
| Urine Sample                    | £8.53   |  |  |  |  |
| Virus PCR                       | £56.00  |  |  |  |  |
| X-ray                           | £46.00  |  |  |  |  |
| ANTIBIOTICS (PER DOSE/COURSE)   |         |  |  |  |  |
| Amoxicillin 125mg (Suspended) * | £1.16   |  |  |  |  |

| Amoxicillin 125mg (IV) *                     | £4.34               |
|--|---------------------|
| Amoxicillin 250mg (Susp.) *                  | £1.33               |
| Cefotaxime 195mg (IV) *                      | £0.48               |
| Cefotaxime 575mg (IV) *                      | £0.66               |
| NURSE TIME (PER HO                           | UR)                 |
| Band 5                                       | £15.43              |
| Band 6                                       | £18.95              |
| Band 7                                       | £22.50              |
| Band 8a                                      | £27.39              |
| DOCTOR TIME (PER HO                          | OUR)                |
| FY1/FY2                                      | £24.24              |
| ST1-3  | £30.79              |
| APNP   | £27.39              |
| Registrar                                    | £39.02              |
| Consultant                                   | £76.11              |
| REFERRAL TO OTHER SPEC                       | CIALTIES            |
| Surgery                                      | £178.55             |
| Medicine                                     | £272.74             |
| ENT  | £146.92             |
| Neuro  | £411.78             |
| INPATIENT ADMISSI                            | ON                  |
| Short stay (HRG PW20C, 3 days non-elective   |                     |
| stay)#                                       | £1,712              |
| Excess bed day charge #                      | £462                |
| Unit costs provided by Alder Hey Finance Tea | ım unless otherwise |
| stated:                                      |                     |

# NHS Reference costs 2016

\* British National Formulary 2017

784 785

Table 2: Descriptive statistics of study participants

| 797 |  |
|-----|--|
| 191 |  |

|                        | MEAN         | MEDIAN     | MI  |             |
|------------------------|--------------|------------|-----|-------------|
|                        | (SD)         | (IQR)      | N   | MAX         |
|                        |              |            | 4   |             |
|                        |              |            | day |             |
| Age                    | 3.28 (3.09)  | 2.17 (3.5) | S   | 15.98 years |
|                        | 53.5%        |            |     |             |
| Gender Male (Freq)     | (3,484)      | -          | -   | -           |
| Temperature            | 38.7 (1.07)  | 38.6 (1.7) | 35  | 41.4        |
| Respiratory rate (bpm) | 29.95 (9.23) | 28 (8)     | 14  | 188         |

|  | 138.7       |          |    |     |
|--|-------------|----------|----|-----|
| Pulse (bpm)                            | (25.98)     | 138 (37) | 22 | 250 |
| MANCHESTER TRIAGE SCALE (MTS)          |             |          |    |     |
| CLASSIFICATION                         |             |          |    |     |
|  | 47.52%      |          |    |     |
| MTS Green (Freq)                       | (3,097)     | -        | -  | -   |
| MTS Yellow (Freq)                      | 8.88% (579) | -        | -  | -   |
| MTS Yellow/Red (Freq)                  | 0.17% (11)  |          |    |     |
|  | 17.06%      |          |    |     |
| MTS Orange (Freq)                      | (1,112)     | -        | -  | -   |
|  | 23.03%      |          |    |     |
| MTS Orange/Red (Freq)                  | (1,501)     |          |    |     |
| MTS Red (Freq)                         | 0.39% (27)  | -        | -  | -   |
| MTS Not recorded (Freq)                | 2.9% (191)  | -        | -  | -   |
| TIMINGS                                |             |          |    |     |
| Time between booking and triage (mins) | 15.3 (14.7) | 11 (18)  | 0  | 71  |
| <10 mins                               | 47.8%       |          |    |     |
| 11-20 mins                             | 24.1%       |          |    |     |
| 21-40 mins                             | 20%         |          |    |     |
| 41-60 mins                             | 5.6%        |          |    |     |
| >61 mins                               | 2.5%        |          |    |     |
| Time between triage and consultation   |             |          |    |     |
| (mins)                                 | 67.9 (52)   | 55 (65)  | 0  | 609 |
| <30 mins                               | 26.9%       |          |    |     |

| 31-60 mins  | 27.7%                          |          |    |     |
|---|--------------------------------|----------|----|-----|
| 61-120 mins   | 30.8%                          |          |    |     |
| 121-180 mins  | 11.4%                          |          |    |     |
| 181-240 mins  | 2.6%                           |          |    |     |
| > 240 mins  | 0.6%                           |          |    |     |
| Time in ED post consultation (mins)   | 68.4 (70.6)                    | 45 (72)  | 0  | 630 |
| <30 mins  | 43.5%                          |          |    |     |
| 30-60 mins  | 15.1%                          |          |    |     |
| 61-120 mins   | 24.8%                          |          |    |     |
| 121-180 mins  | 9.7%                           |          |    |     |
| >181 mins   | 7%                             |          |    |     |
| Total time in ED (mins)   | 151.6 (81.3)                   | 135 (98) | 16 | 729 |
|   |                                |          |    |     |
| <60 mins  | 8.3%                           |          |    |     |
| <60 mins  | 8.3%<br>32.7%                  |          |    |     |
|   |                                |          |    |     |
| 61-120 mins   | 32.7%                          |          |    |     |
| 61-120 mins<br>121-240 mins   | 32.7%<br>46.9%                 |          |    |     |
| 61-120 mins 121-240 mins 241-360 mins   | 32.7%<br>46.9%<br>9.6%         |          |    |     |
| 61-120 mins 121-240 mins 241-360 mins >361 mins   | 32.7%<br>46.9%<br>9.6%         |          |    |     |
| 61-120 mins  121-240 mins  241-360 mins  >361 mins  Inpatient length of stay (Days)                   | 32.7%<br>46.9%<br>9.6%<br>2.5% |          |    |     |
| 61-120 mins  121-240 mins  241-360 mins  >361 mins  Inpatient length of stay (Days)  Not hospitalised | 32.7%<br>46.9%<br>9.6%<br>2.5% |          |    |     |

| Reattendance (Freq) | 3.43% (224) | - | - | - |
|---------------------|-------------|---|---|---|
|                     | 88.9%       |   |   |   |
| Afterhours (Freq)   | (5,798)     | - | - | - |
|                     | 60.1%       |   |   |   |
| Winter (Freq)       | (3,918)     | - | - | - |
| REVIEWING CLINICIAN |             |   | , |   |
| APNP                | 2.73% (178) | - | - | - |
| Consultant          | 7.99% (521) | - | - | - |
| Foundation year 1&2 | 0.91% (59)  | - | - | - |
|                     | 22.05%      |   |   |   |
| Registrar           | (1,437)     | - | - | - |
|                     | 66.32%      |   |   |   |
| ST1-3               | (4,323)     |   |   |   |

Table 3: Health service costs of paediatric febrile illness by sub-group

|             | Num              | Mea              | Std.             | 050/ CI        | Medi  | IOD              | D1       |
|-------------|------------------|------------------|------------------|----------------|-------|------------------|----------|
|             | ber              | n                | dev              | 95% CI         | an    | IQR              | P-valu   |
|             |                  | <del>£223.</del> | <del>£719.</del> | £33.55-        | £51.9 | <del>£22.3</del> |          |
| All         | <del>6,518</del> | <del>55</del>    | <del>65</del>    | £1,275.85      | 2     | <del>5</del>     |          |
| Age         |                  |                  |                  |                |       |                  |          |
|             |                  | £1,00            | £1,46            | £82.39-        | £76.6 | £1,83            |          |
| 0-3months   | 129              | 0.28             | 9.98             | £2,993.37      | 5     | 4.10             |          |
|             |                  | £522.            | £1,73            | £122.08-       | £53.6 | £55.7            |          |
| 3-6 months  | 281              | 33               | 7.66             | £2,123.51      | 3     | 0                |          |
|             |                  | £205.            | £585.            |                | £51.2 | £21.5            |          |
| 6-12 months | 1,041            | 28               | 18               | £28.26-£734.39 | 9     | 0                |          |
|             |                  | £190.            | £594.            |                | £51.6 | £21.6            |          |
| 1-3 years   | 2,498            | 44               | 95               | £13.22-£643.89 | 4     | 0                | p=0.0001 |
|             |                  | £158.            | £501.            | £20.43-        | £51.2 | £19.8            | p 212002 |
| 3-6 years   | 1,547            | 97               | 82               | £1,596.43      | 9     | 0                |          |
|             |                  | £165.            | £485.            |                | £52.9 | £20.7            |          |
| 6-10 years  | 707              | 92               | 04               | £11.14-£843.02 | 8     | 0                |          |

|                               |                 | £408.                                 | £1,03  | £44.97-  | £55.5                         | £40.9                         |          |
|-------------------------------|-----------------|---------------------------------------|--|--|-------------------------------|-------------------------------|----------|
| 10-16 years                   | 315             | 32                                    | 0.12   | £2,188.27  | 5                             | 0                             |          |
| Gender                        |                 |                                       |  |  |                               |                               |          |
|                               |                 | £210.                                 | £600.  |  | £51.2                         | £21.5                         |          |
| Male                          | 3,482           | 17                                    | 23   | £38.45-£818.68   | 9                             | 0                             |          |
|                               |                 | £238.                                 | £835.  |  | £53.1                         | £23.1                         | p=0.000  |
| Female                        | 3,036           | 90                                    | 77   | £14.13-£924.63   | 6                             | 0                             |          |
| NICE NG51 he                  | art rate red fl | ag <sup>27</sup>                      |  |  |                               |                               |          |
|                               |                 | £259.                                 | £848.  | £21.76-  | £54.0                         | £24.6                         | 0.000    |
| Yes                           | 2,797           | 40                                    | 10   | £1,015.89  | 3                             | 0                             | p=0.0001 |
|                               |                 | £196.                                 | £604.  |  | £50.8                         | £20.3                         |          |
|                               |                 |                                       | 20   | 010.27 0700.74   | 7                             | 0                             |          |
| No                            | 3,721           | 59                                    | 38   | £18.36-£699.74   | 7                             | U                             |          |
| NICE NG51 res                 |                 |                                       | 38   | £18.30-£099./4   | /                             | 0                             |          |
|                               |                 |                                       | £1,03  | £18.36-£699./4   | £66.6                         | £70.4                         |          |
|                               |                 | red flag <sup>27</sup>                |  |  |                               |                               |          |
| NICE NG51 res                 | spiratory rate  | red flag <sup>27</sup> £493.          | £1,03  | £89.16-  | £66.6                         | £70.4                         | n=0.000  |
| NICE NG51 res                 | spiratory rate  | <b>red flag<sup>27</sup></b> £493. 92 | £1,03<br>5.52  | £89.16-  | £66.6<br>7                    | £70.4<br>5                    | p=0.000  |
| NICE NG51 res                 | spiratory rate  | £493. 92 £206.                        | £1,03<br>5.52<br>£691.                               | £89.16-<br>£2,011.32                                     | £66.6<br>7<br>£51.2           | £70.4<br>5<br>£21.5           | p=0.000  |
| NICE NG51 res                 | spiratory rate  | £493. 92 £206.                        | £1,03<br>5.52<br>£691.                               | £89.16-<br>£2,011.32                                     | £66.6<br>7<br>£51.2           | £70.4<br>5<br>£21.5           | p=0.000  |
| NICE NG51 res                 | spiratory rate  | £493. 92 £206.                        | £1,03<br>5.52<br>£691.<br>06                         | £89.16-<br>£2,011.32                                     | £66.6<br>7<br>£51.2<br>9      | £70.4<br>5<br>£21.5           | p=0.000  |
| Yes  No  Clinical grade       | 394 6,124       | £493. 92 £206. 15                     | £1,03<br>5.52<br>£691.<br>06                         | £89.16-<br>£2,011.32<br>£23.71-£737.44                   | £66.6<br>7<br>£51.2<br>9      | £70.4<br>5<br>£21.5<br>0      | p=0.000  |
| Yes  No  Clinical grade       | 394 6,124       | £493. 92 £206. 15 £109.               | £1,03<br>5.52<br>£691.<br>06<br>£312.                | £89.16-<br>£2,011.32<br>£23.71-£737.44                   | £66.6<br>7<br>£51.2<br>9      | £70.4<br>5<br>£21.5<br>0      | p=0.000  |
| Yes  No  Clinical grade  APNP | 394<br>6,124    | £493. 92 £206. 15 £109. 52 £315.      | £1,03<br>5.52<br>£691.<br>06<br>£312.<br>67<br>£1,34 | £89.16-<br>£2,011.32<br>£23.71-£737.44<br>£12.74-£741,65 | £66.6 7 £51.2 9 £48.0 1 £73.2 | £70.4 5 £21.5 0 £21.8 0 £40.7 |          |

|                |       | £255. | £702. | £19.40-        | £54.4 | £23.8 |          |
|----------------|-------|-------|-------|----------------|-------|-------|----------|
| Registrar      | 1,437 | 40    | 86    | £1,045.91      | 9     | 0     |          |
|                |       | £199. | £615. |                | £49.7 | £28.0 |          |
| ST1-3          | 4,323 | 68    | 00    | £12.51-£721.02 | 7     | 5     |          |
| Afterhours     |       |       |       |                |       |       |          |
|                |       | £222. | £726. |                | £51.9 | £22.4 |          |
| Yes            | 5,798 | 22    | 36    | £14.77-£776.64 | 2     | 0     |          |
|                |       | £234. | £664. |                | £51.6 | £22.0 |          |
| No             | 720   | 19    | 61    | £11.96-£913.33 | 5     | 0     | p=0.0018 |
| MTS            |       |       |       |                |       |       |          |
| classification |       |       |       |                |       |       |          |
|                |       | £121. | £390. |                | £49.4 | £19.0 |          |
| Green          | 3,098 | 78    | 33    | £15.81-£       | 3     | 5     |          |
|                |       | £424. | £1,02 | £340.69-       | £63.1 | £557. |          |
| Yellow         | 579   | 43    | 7.90  | £508.17        | 0     | 35    |          |
|                |       | £85.7 | £95.2 |                | £52.3 | £16.5 |          |
| Yellow/Red     | 10    | 1     | 4     | £71.73-£99.42  | 3     | 0     | p=0.0001 |
|                |       | £487. | £1,20 | £416.08-       | £68.8 | £77.0 |          |
| Orange         | 1,112 | 16    | 9.15  | £558.24        | 6     | 5     |          |
|                |       | £152. | £491. | £123.44-       | £51.8 | £17.2 |          |
| Orange/Red     | 1,502 | 13    | 60    | £170.56        | 4     | 0     |          |
|                |       | £549. | £813. | £236.47-       | £76.8 | £1,16 |          |
| Red            | 26    | 42    | 99    | £862.35        | 8     | 5.85  |          |
|                |       | £292. | £966. | £154.93-       | £50.8 | £20.4 |          |
| Not recorded   | 191   | 01    | 43    | £429.09        | 7     | 0     |          |

| Final            |       |       |       |               |       |       |        |
|------------------|-------|-------|-------|---------------|-------|-------|--------|
| diagnosis        |       |       |       |               |       |       |        |
| Bacterial        |       |       |       |               |       |       |        |
| Infection/syndr  |       | £988. | £1,78 | £86.89-       | £77.9 | £1,75 |        |
| ome              | 460   | 19    | 1.97  | £2,971.08     | 5     | 7.35  |        |
| Viral            |       |       |       |               |       |       |        |
| Infection/syndr  |       | £294. | £797. | £18.92-       | £51.6 | £24.2 |        |
| ome              | 1,595 | 52    | 43    | £1,082.33     | 4     | 5     |        |
| Inflammatory     |       |       |       |               |       |       |        |
| infection/syndr  |       | £582. | £1,30 | £37.60-       | £63.4 | £1,14 | p=0.00 |
| ome              | 74    | 58    | 2.26  | £1,516.05     | 4     | 0.65  |        |
| Other or trivial |       | £390. | £786. | £22.34-       | £64.0 | £187. |        |
| infection        | 130   | 06    | 27    | £1,243.30     | 4     | 15    |        |
| Unknown          |       | £103. | £286. |               | £51.2 | £18.6 |        |
| cause            | 4,259 | 06    | 52    | £12.40-633.87 | 9     | 0     |        |
| *Kruskal-Wallis  |       |       |       |               |       |       |        |
| test             |       |       |       |               |       |       |        |

Table 6: Determinants of healthcare resource use for paediatric febrile episodes

| CO-EFFICIENT | LN(β<br>)      | <b>EXP</b> (β) | 95% CI (β)<br>LOW | 95% CI (β)<br>HIGH | P-VALUE |
|--------------|----------------|----------------|-------------------|--------------------|---------|
| 0-3m         | 1.26           | 3.54           | 2.589             | 4.85               | 0.001   |
| 3-6m         | 0.79<br>1      | 2.20<br>7      | 1.544             | 3.155              | 0.001   |
| 6-12m        | 0.17<br>1      | 1.18<br>6      | 0.924             | 1.524              | 0.180   |
| 3-6Y         | -<br>0.16<br>4 | 0.84<br>8      | 0.705             | 1.021              | 0.082   |
| 6-10Y        | -<br>0.04<br>6 | 0.95           | 0.738             | 1.235              | 0.724   |
| 10-16Y       | 0.65<br>6      | 1.92<br>7      | 1.399             | 2.654              | 0.001   |

| Gender (Male)            | 0.16           | 0.84<br>9 | 0.736 | 0.978 | 0.024 |
|--------------------------|----------------|-----------|-------|-------|-------|
| Time from Book-in to     | -<br>0.00<br>5 | 0.99<br>4 | 0.990 | 0.999 | 0.013 |
| NICE HR                  | 0.03           | 1.03      | 0.894 | 1.197 | 0.644 |
| NICE RR                  | 0.54           | 1.72<br>1 | 1.289 | 2.299 | 0.001 |
| Time from Triage to Call | -<br>0.00<br>1 | 0.99<br>9 | 0.997 | 1.000 | 0.357 |
| APNP                     | -<br>0.55<br>5 | 0.57      | 0.374 | 0.878 | 0.011 |
| FY1/FY2                  | 1.16           | 3.19      | 2.017 | 5.055 | 0.001 |
| ST1-3                    | -<br>0.16<br>1 | 0.85      | 0.670 | 1.081 | 0.187 |
| Registrar                | -<br>0.06<br>8 | 0.93      | 0.719 | 1.212 | 0.608 |

| After Hours** | 0.14<br>7      | 1.15<br>9 | 0.867 | 1.548 | 0.317 |
|---------------|----------------|-----------|-------|-------|-------|
| Winter        | -<br>0.21<br>5 | 0.80<br>6 | 0.695 | 0.934 | 0.004 |
| MTS Yellow    | 0.86           | 2.38      | 1.905 | 2.979 | 0.001 |
| MTS Orange    | 1.04<br>9      | 2.85      | 2.397 | 3.405 | 0.001 |
| MTS Red       | 1.09           | 2.99      | 1.762 | 5.081 | 0.001 |

#Figures are exponentiated GLM (gamma, log) coefficients, interpreted as x-fold increases versus the reference group. \* Reference group age =1-3 years, reference group clinical grade = consultants, reference group MTS classification = green

<sup>\*\*</sup>Between the hours of 6.30pm and 8a.m Monday to Friday, and all-day Saturday, Sunday and bank holidays.

Table 7: Sensitivity analyses of determinants of healthcare costs for paediatric febrile episodes

|                  | β<br>(BASE-<br>CASE) # | β<br>(BOOT<br>STRAP<br>PED) | MINIMUM β (% LOWER) # | MAXIMUM β<br>(% HIGHER)# | STATISTICALLY<br>SIGNIFICANT* |
|------------------|------------------------|-----------------------------|-----------------------|--------------------------|-------------------------------|
| 0-3 months       | 3.543                  | 3.11                        | 2.16 (39.02%)         | 3.92 (10.69%)            | 100%                          |
| 0-6 months       | 2.207                  | 2.08                        | 1.45 (34.39%)         | 2.68 (21.55%)            | 100%                          |
| 6-12 months      | 1.186                  | 1.27                        | 1.00 (15.75%)         | 1.54 (29.84%)            | 38.38%                        |
| 3-6 years        | 0.848                  | 0.88                        | 0.68 (19.3%)          | 0.98 (15.77%)            | 19.19%                        |
| 6-10 years       | 0.954                  | 1.00                        | 0.74 (22.39%)         | 1.18 (23.63%)            | 0%                            |
| 10-16 years      | 1.927                  | 1.81                        | 1.25 (35.27%)         | 2.10 (8.98%)             | 100%                          |
| Gender<br>(Male) | 0.849                  | 0.90                        | 0.78 (7.91%)          | 0.99 (16.64%)            | 8.08%                         |

|     | me<br>Book-in to | 0.994 | 1.00   | 0.99 (0.24%)      | 1.00 (0.65%)   | 16.16% |
|-----|------------------|-------|--------|-------------------|----------------|--------|
| Tr  | riage)           |       |        |                   |                |        |
| NI  | ICE HR           | 1.034 | 1.03   | 0.89 (14.04%)     | 1.12 (8.75%)   | 0%     |
| NI  | ICE RR           | 1.721 | 1.65   | 1.19 (30.71%)     | 1.99 (15.60%)  | 100%   |
| (Ti | me<br>riage to   | 0.999 | 1.00   | 1.00 (0.14%)      | 1.00 (0.13%)   | 3.03%  |
| AI  | PNP              | 0.573 | 0.69   | 0.37 (36.23%)     | 0.99 (72.91%)  | 28.28% |
| FY  | Y1/FY2           | 3.193 | 3.29   | 1.98 (37.94%)     | 4.06 (27.11%)  | 100%   |
| ST  | Γ1-3             | 0.851 | 0.90   | 0.72 (15.88%)     | 1.01 (18.17%)  | 0%     |
| RE  | EG               | 0.933 | 1.00   | 0.76 (19.02%)     | 1.12 (20.10%)  | 0%     |
| Af  | fter Hours       | 1.159 | 1.19   | 0.90 (21.98%)     | 1.47 (26.54%)  | 2.02%  |
| W   | inter            | 0.806 | 0.79   | 0.68 (15.08%)     | 0.89 (10.11%)  | 98.99% |
|     | TS<br>ellow      | 2.382 | 2.27   | 1.77 (25.67%)     | 2.61 (9.59%)   | 100%   |
|     | TS               | 2.857 | 2.89   | 2.23 (22.08%)     | 3.21 (12.43%)  | 100%   |
| M   | TS Red           | 2.992 | 4.52   | 1.95 (34.80%)     | 6.87 (129.76%) | 100%   |
| Co  | onstant          | 164.8 | 143.50 | 90.33<br>(45.19%) | 179.37 (8.84%) | 100%   |

<sup>#</sup>Figures are exponentiated GLM (gamma, log) coefficients, interpreted as x-fold increases versus the reference group. Reference group age =1-

<sup>3</sup> years, reference group clinical grade = consultants, reference group MTS classification = green

<sup>\*</sup>Proportion of 100 bootstrapped GLM regressions in which p-value was < 0.05